Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
After finishing at $73.28 in the prior trading day, Mirum Pharmaceuticals Inc (NASDAQ: MIRM) closed at $76.19, up 3.97%. In other words, the price has increased by $3.97 from its previous closing price. On the day, 0.52 million shares were traded. MIRM stock price reached its highest trading level at $76.38 during the session, while it also had its lowest trading level at $73.09.
Ratios:
Our goal is to gain a better understanding of MIRM by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.57 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 443.52. For the most recent quarter (mrq), Quick Ratio is recorded 2.97 and its Current Ratio is at 3.13. In the meantime, Its Debt-to-Equity ratio is 1.25 whereas as Long-Term Debt/Eq ratio is at 1.24.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, TD Cowen on September 24, 2025, initiated with a Buy rating and assigned the stock a target price of $95.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 11 ’25 when Brege Laura sold 17,000 shares for $74.40 per share. The transaction valued at 1,264,868 led to the insider holds 15,703 shares of the business.
BJERKHOLT ERIC sold 9,578 shares of MIRM for $728,024 on Sep 12 ’25. The CHIEF FINANCIAL OFFICER now owns 39,945 shares after completing the transaction at $76.01 per share. On Sep 11 ’25, another insider, LAURA BREGE, who serves as the Director of the company, bought 17,000 shares for $74.41 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MIRM now has a Market Capitalization of 3827606528 and an Enterprise Value of 3841952256. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.92 while its Price-to-Book (P/B) ratio in mrq is 14.95. Its current Enterprise Value per Revenue stands at 8.952 whereas that against EBITDA is -116.922.
Stock Price History:
The Beta on a monthly basis for MIRM is 0.76, which has changed by 0.8636826 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, MIRM has reached a high of $78.54, while it has fallen to a 52-week low of $36.88. The 50-Day Moving Average of the stock is 6.40%, while the 200-Day Moving Average is calculated to be 43.94%.
Shares Statistics:
The stock has traded on average 716.80K shares per day over the past 3-months and 769850 shares per day over the last 10 days, according to various share statistics. A total of 50.06M shares are outstanding, with a floating share count of 40.63M. Insiders hold about 19.12% of the company’s shares, while institutions hold 94.04% stake in the company. Shares short for MIRM as of 1759190400 were 7365570 with a Short Ratio of 10.28, compared to 1756425600 on 6861339. Therefore, it implies a Short% of Shares Outstanding of 7365570 and a Short% of Float of 14.66.
Earnings Estimates
Mirum Pharmaceuticals Inc (MIRM) is presently subject to a detailed evaluation by 7.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.12, with high estimates of $0.08 and low estimates of -$0.25.
Analysts are recommending an EPS of between -$0.29 and -$1.0 for the fiscal current year, implying an average EPS of -$0.69. EPS for the following year is $0.03, with 7.0 analysts recommending between $0.78 and -$0.74.
Revenue Estimates
9 analysts predict $130.5M in revenue for. The current quarter. It ranges from a high estimate of $136M to a low estimate of $122.3M. As of. The current estimate, Mirum Pharmaceuticals Inc’s year-ago sales were $90.38MFor the next quarter, 9 analysts are estimating revenue of $136.97M. There is a high estimate of $145M for the next quarter, whereas the lowest estimate is $129.7M.
A total of 10 analysts have provided revenue estimates for MIRM’s current fiscal year. The highest revenue estimate was $519.59M, while the lowest revenue estimate was $491.6M, resulting in an average revenue estimate of $506.34M. In the same quarter a year ago, actual revenue was $336.89MBased on 10 analysts’ estimates, the company’s revenue will be $606.57M in the next fiscal year. The high estimate is $653.11M and the low estimate is $566.08M.
